论文部分内容阅读
目的探讨炔雌醇醋酸环丙孕酮联合二甲双胍治疗肥胖型多囊卵巢综合征(PCOS)患者的临床疗效。方法选取2012年3月至2014年4月在德惠市人民医院治疗的86例肥胖型PCOS患者作为研究对象,根据治疗时间先后将其分为观察组和对照组,各43例。对照组患者给予炔雌醇醋酸环丙孕酮单独治疗,观察组患者在对照组基础上口服二甲双胍,比较两组患者治疗前后体重指数(BMI)、空腹血糖(FBG)以及空腹胰岛素(FIN)、睾酮(T)、雌二醇(E2)、黄体生成素(LH)、促卵泡生成素(FSH)、催乳素(PRL)水平。结果治疗后,观察组患者的BMI、FBG、FIN水平均明显低于对照组,差异均有统计学意义(均P<0.05);治疗后,观察组患者的T、LH水平均明显低于对照组,而两组患者的FSH、E2、PRL水平差异均无统计学意义(均P>0.05)。结论炔雌醇醋酸环丙孕酮联合二甲双胍治疗肥胖型PCOS患者临床效果明显,患者BMI、FBG、FIN、T、LH水平明显下降。
Objective To investigate the clinical effect of ethinyl estradiol and cyproterone acetate combined with metformin in the treatment of patients with obese polycystic ovary syndrome (PCOS). Methods Totally 86 obese patients with PCOS who were treated in Dehui People’s Hospital from March 2012 to April 2014 were selected as study subjects and divided into observation group and control group according to the treatment time. Patients in the control group were given ethinyl estradiol and cyproterone acetate alone. Patients in the observation group were given metformin orally on the basis of the control group. Body mass index (BMI), fasting blood glucose (FBG) and fasting insulin (FIN) were compared between the two groups before and after treatment. (T), estradiol (E2), luteinizing hormone (LH), follicle stimulating hormone (FSH) and prolactin (PRL). Results After treatment, the levels of BMI, FBG and FIN in the observation group were significantly lower than those in the control group (all P <0.05); after treatment, the levels of T and LH in the observation group were significantly lower than those in the control group There was no significant difference in the levels of FSH, E2 and PRL between the two groups (all P> 0.05). Conclusion Ethinylestradiol and cyproterone acetate combined with metformin are effective in treating obese patients with PCOS. The levels of BMI, FBG, FIN, T and LH were significantly decreased.